Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer's $51M upfront equity stake plus up to $635M milestones expands its AAV-directed gene therapy portfolio; structured as an option-to-acquire pending…
VTX-801 has FDA and EC orphan drug designations; current Wilson disease treatments suffer from inadequate efficacy or substantial adverse effects, and liver…
Pfizer agreed to manufacture VTX-801 at its Chapel Hill, NC facility ahead of a 2021 Phase I/II start—Vivet CEO emphasized that gene therapy manufacturing is…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer made a 15% equity investment in Vivet Therapeutics with an exclusive option to acquire all remaining shares for up to euro 560 million ($635M total). Targets VTX-801, an AAV gene therapy for Wilson disease, plus Vivet's broader gene therapy pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Vivet Therapeutics S.A.S. (this deal) | 2019 | $635M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Pfizer Inc. deals · Rare Disease deals